Vaccination of adults with Wistar RA 27/3 rubella vaccine.
Thirty-three adults were vaccinated subcutaneously with Wistar RA. 27/3 (live attenuated) rubella vaccine at the Wellcome Research Laboratories, Beckenham. All subjects with pre-vaccination haemagglutinating-inhibiting antibody titres of 1/20 or less and three of seven subjects with pre-vaccination titres of 1/40 showed at least fourfold rises of titre. Reactions encountered were mild and of short duration.
D000328:Adult; D000906:Antibodies / Q000032:analysis; D005260:Female; D005334:Fever / Q000139:chemically induced; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007279:Injections, Subcutaneous; D007592:Joint Diseases / Q000139:chemically induced; D008297:Male; D010612:Pharyngitis / Q000139:chemically induced; D011247:Pregnancy; D011258:Pregnancy Tests; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000009:adverse effects; D012412:Rubella virus / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage*
D000906:Antibodies; D012411:Rubella Vaccine; D014765:Viral Vaccines